While Abivax ADR has underperformed by -2.52%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ABVX rose by 5.87%, with highs and lows ranging from $14.16 to $4.77, whereas the simple moving average jumped by 0.60% in the last 200 days.
On March 20, 2025, Morgan Stanley started tracking Abivax ADR (NASDAQ: ABVX) recommending Equal-Weight. A report published by JMP Securities on December 04, 2024, Initiated its previous ‘Mkt Outperform’ rating for ABVX. Laidlaw also rated ABVX shares as ‘Buy’, setting a target price of $48 on the company’s shares in an initiating report dated July 29, 2024. BTIG Research Initiated an Buy rating on May 20, 2024, and assigned a price target of $43. Piper Sandler initiated its ‘Overweight’ rating for ABVX, as published in its report on April 29, 2024. Guggenheim’s report from April 29, 2024 suggests a price prediction of $50 for ABVX shares, giving the stock a ‘Buy’ rating. Morgan Stanley also rated the stock as ‘Equal-Weight’.
Analysis of Abivax ADR (ABVX)
To gain a thorough understanding of Abivax ADR’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -147.48% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 1.82, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and ABVX is recording an average volume of 217.97K. On a monthly basis, the volatility of the stock is set at 6.75%, whereas on a weekly basis, it is put at 5.41%, with a gain of 1.31% over the past seven days. Furthermore, long-term investors anticipate a median target price of $32.57, showing growth from the present price of $7.75, which can serve as yet another indication of whether ABVX is worth investing in or should be passed over.
How Do You Analyze Abivax ADR Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 12.35%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 39.28% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
ABVX shares are owned by institutional investors to the tune of 39.28% at present.
